Drug intelligence / Profile preview

lidocaine + bupivacaine + epinephrine (NYU Langone Health)

Development stage
Phase 4
Lead developer
NYU Langone Health
Modality
Small Molecules
Administration
Perineural
01

Overview

DR SSB (Distal Radius Single Shot Block) is a trial-specific regional anesthetic combination developed by NYU Langone Health for the management of postoperative pain following distal radius fracture fixation. The intervention consists of a single-shot peripheral nerve block using a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% bupivacaine with 1:300,000 epinephrine. Lidocaine provides a rapid onset of anesthesia, while bupivacaine offers a prolonged duration of analgesic effect. Epinephrine is included as a vasoconstrictor to delay systemic absorption, thereby extending the duration of the block and reducing potential systemic toxicity. This combination is administered perineurally to block voltage-gated sodium channels, preventing the transmission of pain signals from the surgical site. It has been evaluated in Phase 4 clinical trials (NCT01843309) to compare its efficacy against continuous infusion techniques, such as the On-Q pump, in controlling immediate postoperative pain and reducing rebound pain and opioid consumption.

Other names
Distal Radius Single Shot BlockSingle Shot Peripheral Nerve Block
02

Targets

ADRA1A (α1A)ADRB1 (β1)β-AR (Beta-adrenergic receptor family)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine + bupivacaine + epinephrine (NYU Langone Health).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + bupivacaine + epinephrine (NYU Langone Health).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call